Table 3 Average relative volumes of PTVs covered by 95% of prescription dose ( PV 95 ), and MPV 95 and STDPV 95 , and average ipsilateral lung volumes receiving more than 20Â Gy ( LV 20 ) and Mean lung dose ( PM LD ) (Gy) from CVCT, MIP3, AVG and EE plans (treatment uncertainties included)
From: Evaluation and comparison of New 4DCT based strategies for proton treatment planning for lung tumors
| Â | Case | A | B | C | D | E | F | G | H | I | J | K | L | MPV 95 | STDPV 95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PV 95 (%) | CVCT plan | 96.1 | 98.5 | 100 | 99.9 | 99.5 | 95.4 | 95.6 | 99.8 | 99.9 | 99.7 | 98.9 | 97.8 | 98.4 | 1.7 |
MIP3 plan | 98.4 | 99.1 | 100 | 100 | 99.9 | 100 | 99.7 | 99.8 | 99.8 | 99.8 | 99.3 | 97.8 | 99.5 | 0.7 | |
AVG plan | 89.8 | 94.4 | 100 | 100 | 100 | 100 | 98.5 | 99.8 | 99.8 | 99.8 | 99.5 | 97.0 | 98.2 | 3.1 | |
EE plan | 96.8 | 99.7 | 100 | 99.9 | 100 | 100 | 99.6 | 99.9 | 100 | 99.8 | 99.8 | 97.4 | 99.4 | 1.1 | |
LV 20 (%) | CVCT plan | 3.9 | 8.0 | 13.6 | 7.6 | 13.7 | 18.7 | 23.8 | 12.1 | 20.0 | 25.7 | 32.3 | 30.3 | Â | Â |
MIP3 plan | 5.1 | 8.4 | 15.1 | 9.3 | 13.7 | 18.6 | 23.0 | 11.5 | 18.2 | 25.9 | 32.8 | 30.8 | Â | Â | |
AVG plan | 2.6 | 7.1 | 13.4 | 7.9 | 13.2 | 19.0 | 20.5 | 11.9 | 19.9 | 25.7 | 33.4 | 31.0 | Â | Â | |
EE plan | 4.0 | 8.2 | 13.4 | 7.9 | 13.2 | 19.1 | 21.3 | 11.2 | 21.0 | 25.8 | 33.1 | 31.0 | Â | Â | |
PM LD (Gy) | CVCT plan | 2.4 | 3.9 | 6.7 | 4.3 | 6.3 | 8.4 | 10.8 | 6.7 | 9.1 | 13.0 | 15.7 | 14.7 | Â | Â |
MIP3 plan | 2.8 | 4.0 | 7.1 | 5.1 | 6.2 | 8.8 | 10.1 | 6.5 | 8.4 | 12.7 | 16.0 | 15.0 | Â | Â | |
AVG plan | 1.7 | 3.4 | 6.6 | 4.4 | 6.1 | 8.6 | 9.6 | 6.5 | 8.8 | 12.7 | 16.3 | 15.1 | Â | Â | |
| Â | EE plan | 2.4 | 3.9 | 6.5 | 4.4 | 6.1 | 8.7 | 9.9 | 6.2 | 9.2 | 12.8 | 16.5 | 15.2 | Â | Â |